Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Forster

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 11, 2009
Adjuvant therapy with the monoclonal antibody Edrecolomab plus fluorouracil-based therapy does not improve overall survival of patients with stage III colon cancerAnthony L A Fields, Alan Keller, Lee Schwartzberg, et al.
Fungal Genetics and Biology : FG & B|March 24, 2006
Transcriptome analysis of Neotyphodium and Epichloë grass endophytesSilvina Felitti, Katherine Shields, Marc Ramsperger, et al.
The New England Journal of Medicine|December 29, 2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancerCharles E Geyer, John Forster, Deborah Lindquist, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 11, 2009
Adjuvant therapy with the monoclonal antibody Edrecolomab plus fluorouracil-based therapy does not improve overall survival of patients with stage III colon cancerAnthony L A Fields, Alan Keller, Lee Schwartzberg, et al.
Fungal Genetics and Biology : FG & B|March 24, 2006
Transcriptome analysis of Neotyphodium and Epichloë grass endophytesSilvina Felitti, Katherine Shields, Marc Ramsperger, et al.
The New England Journal of Medicine|December 29, 2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancerCharles E Geyer, John Forster, Deborah Lindquist, et al.
Pageof 2